持续看好[财迷]_老虎社区_美港股上老虎

晚晚不说晚安
2021-06-15

持续看好[财迷]

Time to Load up on Atossa Shares? This Analyst Thinks So

The stock market, like any other industry, is riddled with clichés. One of the most commonly used is

Time to Load up on Atossa Shares? This Analyst Thinks So

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":187175322,"tweetId":"187175322","gmtCreate":1623748098366,"gmtModify":1623748098366,"author":{"id":3555398020973593,"authorId":3555398020973593,"authorIdStr":"3555398020973593","name":"晚晚不说晚安","avatar":"https://static.tigerbbs.com/fe6c50147f318e4c7674cc804cb763f3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":88,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>持续看好<span>[财迷]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p>持续看好<span>[财迷]&nbsp;</span></p></body></html>","text":"持续看好[财迷]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/187175322","repostId":2143973689,"repostType":2,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://www.laohu8.com/m/news/2143973689?lang=&edition=full","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIME":"Clockwise Core Equity & Innovation ETF","ATOS":"Atossa Genetics Inc"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1795,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}